Semax and Selank are heptapeptides developed at Soviet and then Russian academic institutions beginning in the 1980s. Both are approved in Russia and Ukraine for neurological indications, with prescription use spanning decades. Neither holds regulatory approval in Western markets, where they're studied as research compounds. Despite the shared origin, their mechanisms, receptor targets, and clinical profiles are substantially different. Semax is principally a cognitive enhancer and neuroprotectant; Selank is primarily an anxiolytic-immunomodulator.
Semax: The BDNF Upregulator
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analogue. The core four-residue melanocortin sequence MEHF is extended with a Pro-Gly-Pro tripeptide tail that improves stability and CNS penetration via the intranasal route. Its most reproducible molecular effect is robust upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, particularly in the hippocampus and prefrontal cortex.
BDNF is one of the most studied molecules in neuroscience. It promotes neuronal survival, synaptic plasticity, and long-term potentiation, the cellular basis of learning and memory. BDNF deficiency is associated with depression, Alzheimer's disease, and age-related cognitive decline. A compound that reliably and safely upregulates BDNF would have substantial therapeutic interest. That's why Semax has attracted the attention it has.
- BDNF/TrkB upregulation: Primary mechanistic signature; dose-dependent and rapid-onset
- Melanocortin receptor partial agonism: Primarily MC4R and MC5R; mediates attention and arousal effects
- Dopaminergic system modulation: Increases dopamine turnover in frontal cortex and striatum
- Serotonin receptor sensitivity: Modulates 5-HT receptor responsiveness
- Hippocampal neurogenesis promotion: Consistent with BDNF-dependent mechanisms
Clinical applications in Russia include acute ischemic stroke (within the therapeutic window — Semax is given intranasally in acute stroke care in some Russian facilities), transient ischemic attack, optic nerve atrophy, ADHD, and age-related cognitive decline. The BDNF mechanism has generated significant Western research interest as a potential adjunct treatment for treatment-resistant depression, though controlled trial data accessible to international researchers remains sparse.
Selank: Anxiolytic Without Sedation
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is derived from the endogenous immunopeptide tuftsin (TKPR), a tetrapeptide naturally generated from IgG, extended with a PGP tripeptide for stability. Its approval in Russia is for anxiety and asthenic disorders. Pharmacologically, it represents a mechanistically distinct path to anxiolysis — neither a benzodiazepine agonist, an SSRI, nor an antihistamine.
Unlike classical benzodiazepines, Selank does not produce sedation, muscle relaxation, or withdrawal symptoms, and shows no evidence of tolerance development in animal models over extended administration.
— Seredenin SB & Voronina TA, Russian Journal of Pharmacology, 2009
Proposed mechanisms include: potentiation of GABAergic tone via enkephalin system modulation (indirect GABA-A enhancement without direct receptor binding), inhibition of enkephalin-degrading enzymes (prolonging endogenous opioid activity), and cytokine modulation — specifically IL-6 upregulation and TNF-α downregulation. The immunomodulatory component is genuinely unusual for an anxiolytic and may explain additional reported effects on fatigue and immune function.
Semax and Selank Safety: What Is Known
Both peptides have multi-decade prescription use histories in Russia, providing a degree of real-world safety data that most Western research peptides entirely lack. Reported adverse effects from clinical use are generally mild:
- Semax adverse effects: Nasal irritation (intranasal administration), occasional headache, rare cases of excessive stimulation or anxiety at high doses; no reported cases of addiction or dependence
- Selank adverse effects: Mild sedation at higher doses despite the anxiolytic-without-sedation characterization at lower doses; nasal irritation; rare mood disturbances
- Both peptides: No established drug interactions have been formally characterized; avoid combining with other CNS-active compounds without careful monitoring
- Long-term data: Soviet and Russian prescription data spans decades for some patient populations, suggesting acceptable long-term tolerability — though this data is not published in a form accessible to international systematic review
A significant concern for Western researchers is product quality. Semax and Selank obtained from unregulated vendors may differ substantially in purity, concentration, and stability from the approved Russian pharmaceutical formulations. The intranasal route is more forgiving than injection for minor impurities, but endotoxin content remains a concern with any non-GMP product.
Comparative Summary and Research Outlook
Semax is better characterized as a cognitive enhancer and neuroprotectant; Selank as an anxiolytic-immunomodulator. Research interest in their combined use is increasing — the hypothesis being that Semax's BDNF upregulation and pro-cognitive effects complement Selank's anxiety reduction, potentially improving both the subjective experience of cognitive work and the neurobiological substrate that makes such work possible.
For Western researchers, the most important gaps are: lack of RCTs meeting current international standards, limited pharmacokinetic data in Western populations, and absence of independent replication of the most striking mechanistic claims. The approved Russian indication status distinguishes these compounds from most research peptides and warrants continued serious research attention.
References & primary sources
Most of the human clinical literature on Semax and Selank is published in Russian-language journals; English-language summaries and translated abstracts are indexed on PubMed under 'Semax' and 'Selank'. The selected English-accessible sources below are representative; English-language coverage substantially understates the underlying corpus.
- Kost NV, Sokolov OY, Gabaeva MV, et al. (2001) Anxiolytic activity of the peptide Selank in white rats. Bulletin of Experimental Biology and Medicine 132:917-920.
- Inozemtseva LS, Karpenko EA, Dolotov OV, et al. (2008) Intranasal administration of the peptide Semax affects expression of brain-derived neurotrophic factor and trkB in the basal forebrain of rats. Doklady Biological Sciences 421:241-243.
- Khavinson VK, Malinin VV. (2005) Gerontological aspects of genome peptide regulation. Karger Publishers (monograph).Survey of the Russian peptide-regulator school of pharmacology in which Semax/Selank were developed.
- PubMed search results. (ongoing) Semax and Selank — primary literature index. [link]Live-search link to the broader literature, much of which is Russian-language with English abstracts only.
Questions and answers
What is Semax's most reproducible molecular effect?
Robust upregulation of brain-derived neurotrophic factor and its receptor TrkB, particularly in the hippocampus and prefrontal cortex. Semax is an ACTH(4-7) analogue in which the core melanocortin sequence is extended with a Pro-Gly-Pro tail that improves stability and central nervous system penetration by the intranasal route.
How does Selank differ from a benzodiazepine?
It is mechanistically distinct, being neither a benzodiazepine agonist, an SSRI nor an antihistamine. In animal models it does not produce sedation, muscle relaxation or withdrawal symptoms, and shows no evidence of tolerance over extended administration. Proposed mechanisms include potentiation of GABAergic tone through enkephalin system modulation rather than direct receptor binding.
What distinguishes these two compounds from most research peptides?
Approved indication status in Russia and multi-decade prescription use histories, which provide a degree of real-world safety data that most Western research peptides entirely lack. Selank's Russian approval is for anxiety and asthenic disorders.
What are the main evidence gaps for Western researchers?
A lack of randomised controlled trials meeting current international standards, limited pharmacokinetic data in Western populations, and an absence of independent replication of the most striking mechanistic claims.